The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Zimmer Wins First U.S. Trial over NexGen Flex Knee Devices

Zimmer Wins First U.S. Trial over NexGen Flex Knee Devices

November 10, 2015 • By Jessica Dye

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Indiana-based medical device manufacturer Zimmer Biomet Holdings Inc. on Friday was cleared of liability in the first of more than 900 U.S. lawsuits to go to trial over claims that its NexGen Flex knee replacements were prone to painful, motion-impairing loosening.

You Might Also Like
  • Johnson & Johnson Hit with $500 Million Verdict in Trial over Hip Implants
  • U.S. Judge Cuts $500 Million Verdict over Johnson & Johnson Hip Implants
  • Verdict: Johnson & Johnson to Pay More Than $1 Billion for Defective Hip Implants

Following a three-week trial in the U.S. District Court for the Northern District of Illinois, jurors returned a verdict for Zimmer in the lawsuit brought by Kathy Batty, according to Zimmer spokeswoman Monica Kendrick.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Batty, who suffers from degenerative joint disease, underwent a total knee replacement on both knees in 2009 using Zimmer’s NexGen Flex system. Within a year, she said she began to experience severe pain, leading her to replace the implants in 2011. She and other plaintiffs had accused the company of designing a flawed product and failing to warn doctors about its potential risks.

Although the outcome of Batty’s trial will not be binding on other cases, it is a critical early win for Zimmer in the consolidated federal litigation, which currently contains more than 900 cases. The victory is particularly significant because lead plaintiffs’ lawyers had selected Batty’s case for the first trial, signaling their belief that it was one of the “strongest cases in this litigation,” Kendrick said in a statement.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Kendrick said the company was pleased with the verdict and looked forward to defending its NexGen Flex products “in as many trials as are necessary.” Lead lawyers for Batty did not immediately return requests for comment.

Zimmer’s NexGen Flex was cleared for sale by the U.S. Food and Drug Administration in 2007, and was designed to offer greater flexibility than standard knee devices.

Plaintiffs said the marketing for the devices falsely implied that patients could engage in activities involving frequent knee flexing, when in fact the devices could not withstand the additional force and strain. They said that a flaw in the NexGen Flex design could cause it to loosen prematurely, requiring additional surgery to fix or replace.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Zimmer has denied that the devices are defective and said they have a successful track record. It argued that Batty’s alleged injuries may have been caused by other factors, such as infection.

Zimmer Holdings Inc.’s $14 billion purchase of rival device maker Biomet was approved earlier this year, creating Zimmer Biomet.

The case is Batty v. Zimmer, U.S. District Court for the Northern District of Illinois, No. 12-6279.

Filed Under: Conditions, Drug Updates, Osteoarthritis, Pharma Co. News Tagged With: joint degeneration, knee replacement, Pain, Zimmer Biomet Holdings Inc.

You Might Also Like:
  • Johnson & Johnson Hit with $500 Million Verdict in Trial over Hip Implants
  • U.S. Judge Cuts $500 Million Verdict over Johnson & Johnson Hip Implants
  • Verdict: Johnson & Johnson to Pay More Than $1 Billion for Defective Hip Implants
  • Clinical Trials: Zilretta Promising for Knee OA Pain & Golimumab Completes Phase 3 Trial

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.